June 30, 2008
TARO BOARD OF DIRECTORS TO EVALUATE UNSOLICITED TENDER OFFER FROM SUN PHARMACEUTICAL INDUSTRIES LTD.; TARO ASKS SHAREHOLDERS NOT TO TAKE ANY ACTION AT THIS TIME
Hawthorne, NY, June 30, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro” or the “Company”) (Pink Sheets: TAROF) said today that it would have no formal comment on the unsolicited tender offer commenced today by a subsidiary of Sun Pharmaceutical Industries Ltd. (“Sun”), for all shares of Taro common stock at a price of $7.75 per share until Taro's Board of Directors has an opportunity to review and evaluate the full details of the offer.
More 
June 23, 2008
TARO RECEIVES FINAL FDA APPROVAL FOR RX CETIRIZINE HYDROCHLORIDE SYRUP ANDA Generic Equivalent to Zyrtec® Syrup
Hawthorne, NY, June 23, 2008 -- Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF, “Taro”, the “Company”) reported today that it has received final approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for prescription Cetirizine Hydrochloride Syrup, 1 mg / 1 mL (“cetirizine syrup”). Taro had received tentative approval for this ANDA in October 2007.
More
June 19, 2008
TARO SENDS LETTER TO UPDATE SHAREHOLDERS ON LATEST DEVELOPMENTS REGARDING THE TERMINATED SUN MERGER AGREEMENT
Hawthorne, NY, June 19, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) today announced that it is sending a letter to its shareholders updating them on certain developments regarding the previously announced termination of its merger agreement with a subsidiary of Sun Pharmaceutical Industries Ltd.
More
May 28, 2008
TARO TERMINATES MERGER AGREEMENT WITH SUN PHARMACEUTICAL INDUSTRIES LTD.
Hawthorne, NY, May 28, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) today announced that its Board of Directors unanimously voted to terminate the May 18, 2007 merger agreement (the “Merger Agreement”) between the Company and Aditya Acquisition Company Ltd., a subsidiary of Sun Pharmaceutical Industries Ltd. (“Sun,” Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715). The Merger Agreement provided for the acquisition of Taro by Sun for $7.75 per share and allowed either party to terminate after December 31, 2007.
More
April 28, 2008
TARO REACHES AGREEMENT IN PRINCIPLE TO SETTLE SECURITIES LAWSUIT
Hawthorne, NY, April 28, 2008. Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) announced today that the parties in the purported securities class action captioned Loretta Zwickel v. Taro Pharmaceutical Industries Ltd., et al., Case No. 04-CV-05969 (United States District Court for the Southern District of New York) have reached an agreement in principle to settle all claims asserted against all defendants in the action. The settlement is subject to the execution of definitive documentation, notice to the purported shareholder class and final approval of the settlement by the court at a hearing to be scheduled in the near future.
More
April 22, 2008
TARO RECEIVES FINAL FDA APPROVAL FOR CETIRIZINE HYDROCHLORIDE ORAL SOLUTION ANDA
Generic Equivalent to Over-the-Counter Zyrtec® Oral Solution
Hawthorne, NY, April 22, 2008 -- Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF, “Taro”, the “Company”) reported today that it has received final approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for cetirizine hydrochloride oral solution, 1 mg / 1 mL (“Cetirizine Oral Solution”). The product will be marketed by Taro’s U.S. affiliate, Taro Pharmaceuticals U.S.A., Inc.
More
April 10, 2008
TARO APPOINTS NEW CHIEF FINANCIAL OFFICER Hawthorne, NY, April 10, 2008. Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) announced today that Ron Kolker, C.P.A., has been appointed to the position of Senior Vice President, Chief Financial Officer of the Company and of the Company’s U.S. subsidiary, Taro Pharmaceuticals U.S.A., Inc. (“Taro USA”).
Mr. Kolker joined Taro in 1994 and has held a number of roles in finance at the Company with increasing responsibility. He most recently held the position of Group Vice President, Corporate Controller in both the Company and Taro USA, and also served as the Company’s Interim Chief Financial Officer for part of 2007. Mr. Kolker is a Certified Public Accountant and holds an MBA in Finance and Accounting. Mr. Kolker replaces Thomas E. McClary, who is no longer with the Company.
More
April 3, 2008
TARO RECEIVES TENTATIVE FDA APPROVAL FOR LAMOTRIGINE TABLETS ANDA Generic Equivalent to GlaxoSmithKline’s Lamictal® Tablets, 25 mg, 100 mg, 150 mg and 200 mg
Hawthorne, NY, April 3, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” the "Company,” Pink Sheets: TAROF) reported today that it has received tentative approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for Lamotrigine Tablets 25 mg, 100 mg, 150 mg, and 200 mg (“Lamotrigine Tablets”).
More
March 25, 2008
TARO RECEIVES FDA APPROVAL FOR ONDANSETRON HYDROCHLORIDE INJECTION USP, 2 mg/mL ANDA
Generic Equivalent to GlaxoSmithKline’s Zofran® Injection
Hawthorne, NY, March 25, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) reported today that it has received approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for Ondansetron Hydrochloride Injection USP, 2 mg/mL (“Ondansetron Injection”).
More
February 19, 2008
TARO PROVIDES PRELIMINARY 2007 FULL YEAR RESULTS
Hawthorne, New York, Febrary 19, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” Pink Sheets: TAROF) today provided information for the year ended December 31, 2007.
The Company cautioned that the financial information being presented is both unaudited and subject to further review and possible change. Additionally, these results do not provide complete financial information and both the 2006 and the 2007 results are subject to audit by the Company's outside auditors. These results have not been and will not be subject to quarterly review procedures. However, subject to the foreging caveats, the Company believes that the information below represents the best information currently available to Taro management.
More
January 22, 2008
TARO RECEIVES FDA APPROVAL OF NEW DRUG APPLICATION FOR FLO-PREDTM PREDNISOLONE ACETATE ORAL SUSPENSION
Hawthorne, New York, January 22, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” Pink Sheets: TAROF) reported today that its U.S. affiliate, Taro Pharmaceuticals U.S.A., Inc ("Taro USA") has received approval from the U.S. Food and Drug Administration for its New Drug Application (NDA) for Flo-PredTM (prednisolone acetate oral suspension) equivalent to 5 mg/5 mL and 15 mg/5 mL prednisolone in Taro's patent-protected NonSpilTM liquid drug delivery system.
More
January 09, 2008
TARO TO LAUNCH OXCARBAZEPINE IN THE UNITED STATES
Hawthorne, New York, January 9, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” Pink Sheets: TAROF) reported today that it settled a pending lawsuit with Novartis and will be launching Oxcarbazepine Tablets 150 mg, 300 mg, and 600 mg (“Oxcarbazepine Tablets”) in the United States.
More
January 07, 2008
TARO TO CHALLENGE ASSESSMENT ORDER FROM ISRAEL INCOME TAX AUTHORITY
Hawthorne, NY, January 7, 2008 - Taro Pharmaceutical Industries Ltd. Company Says Order Is Confiscatory and Reflects Double Taxation; May Seek Intervention of U.S. Government
More
December 06, 2007
Taro provides Preliminary 2007 Interim Results and updates status of 2006 Financial Statements.
Hawthorne, NY, December 6, 2007 - Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) today provided information for the year ended December 31, 2006 and for the nine months ended September 30, 2007, and provided an update on the Company’s progress in completing its financial statements for the year ended December 31, 2006.
More
September 20, 2007
Taro Receives FDA Approvals For Ciclopirox Topical Solution, 8% (Nail Lacquer) And Grape Flavor formulation Of Loratadine Syrup, 5mg
Generic Equivalents to Penlac® Nail Lacquer Topical Solution and Claritin® Syrup
More
August 16, 2007
Taro To Reschedule Shareholders Meeting On Proposed Merger With Sun Following The Availability Of Financial Results
More
July 23, 2007
Taro Postpones Shareholder Meetings on Proposed Merger with Sun until September 25, 2007
Sun To Exercise Warrants, Providing Additional Liquidity to Taro
More
July 3, 2007
Taro Receives Final Approval for Terbinafine HCL Cream 1% ANDA
Generic Equivalent to Lamisil(R) Cream
More
June 12, 2007
Taro Schedules Shareholders Meeting On Merger With Sun
More
May 21, 2007
Taro Merger with Sun Proceeds after Favorable Court Ruling in Israel
Temporary Injunction Requested by Templeton Not Issued
Decrease of Interim Financing by 9.5%
More
May 20, 2007
Sun Pharmaceutical Industries Agrees to Acquire Taro Pharmaceutical Industries in Transaction Valued at $454 Million
First Investment in Israel by Multinational Pharmaceutical Company
More
March 27, 2007
Taro Receives Tentative Approval For Ciclopirox Topical Solution, 8% (Nail Lacquer) ANDA
Generic Equivalent to Penlac® Nail Lacquer Topical Solution, 8%
More
March 20, 2007
Taro Files 2005 Form 20-F Following Completion of 2005 Audit
More
February 26, 2007
Taro Receives Tentative Approval for Ranitidine Syrup ANDA
Generic Equivalent of Zantac® Syrup
More
February 5, 2007
Results of T2000 Clinical Studies in Essential Tremor Published in the Journal Movement Disorder
More
December 12, 2006
Taro Shares to be Delisted From Nasdaq
Company Shares Expected to Trade on Pink Sheets
More
November 16, 2006
Taro Receives Extension of Time from Nasdaq Panel for Filing of 2005 Form 20-F
More
November 13, 2006
Taro Receives Marketing Authorization in UK For Etopan XL Tablets 600 mg, Etodolac
Company Also Receives UK Approval for Tarodent Mouthwash
More
November 8, 2006
Taro Receives ANDA Approval For Meloxicam Tablets, 7.5 mg and 15 mg, Generic Equivalent to Mobic
Company Also Receives Tentative ANDA Approval for Cetirizine Syrup, Generic Equivalent to Zyrtec
More
October 30, 2006
Taro Receives Investigation Report
More
October 20, 2006
Report To Taro From Independent Counsel Delayed, Expected By October 27, 2006
More
October 18, 2006
Taro Receives Notice Of Allowance For U.S. Patent For Treatment Of Essential Tremor
Patent Covers the Company’s Proprietary Non-Sedating Barbiturate Compounds
More
October 5, 2006
Taro Expects to Receive Report From Independent Counsel by October 20, 2006
More
September 13, 2006
Taro Receives Extension of Time to File 2005 Form 20-F From Nasdaq Panel
More
September 8, 2006
Taro Announces Filing Of ANDA For Oxcarbazepine Tablets 150, 300 And 600 mg
More
September 6, 2006
Taro Receives ANDA Approval for Extended Phenytoin Sodium Capsules, USP 100 MG
Extended Release Capsules are Generic Equivalent to Pfizer’s Dilantin® Kapseals®
Taro’s Irish Affiliate Also Received its First ANDA Approvals for Sterile Products
More
August 29, 2006
Taro Provides Update on Filing of 2005 Form 20-F
More
July 21, 2006
Taro Receives Nasdaq Notice of Possible Delisting for Delayed Filing of 2005 Form 20-F
More
July 18, 2006
Taro Receives Approval For Metronidazole Topical Gel USP, 0.75 Percent ANDA
More
July 18, 2006
Taro Expects to Complete 2005 Audit in August
More
June 22, 2006
Taro Provides Estimates for 2005 Sales and Net Income and Will Restate 2003 and 2004 Results; Non-Cash Adjustments to 2003 and 2004 Will Reflect New Information Used in Estimating Accounts Receivable Reserves
More
May 15, 2006
Taro to Begin Dose Escalation Study of T2000 in Canada to Evaluate Efficacy in Essential Tremor
More
April 24, 2006
Taro Receives Tentative ANDA Approvals For Carvedilol Tablets And Ondansetron HCL Tablets
More
April 20, 2006
Taro to Report Fourth Quarter and Full Year 2005 Results Following Completion of Auditors' Work
More
March 23, 2006
Taro Receives Tentative Approval For Terbinafine HCl Cream 1% ANDA; Generic Equivalent to Lamisil® Cream
More
March 15, 2006
Taro Receives Final Approval for Mometasone Furoate Topical Solution USP, 0.1% (Lotion) ANDA; Generic Equivalent to Elocon(R) Lotion
More
March 8, 2006
Taro to Report Fourth Quarter 2005 Results by Early April 2006
More
January 26, 2006
Taro Receives Tentative Approval For Augmented Betamethasone Dipropionate Lotion ANDA
More
January 13, 2006
Taro Reports ‘A’ Bond Rating in Israel
More
January 5, 2006
Taro And J.B. Chemicals To Collaborate On Product Development For U.S. And Other Markets
More
December 29, 2005
Taro And Alkem To Collaborate On Product Development For U.S. And Other Markets
More
November 17, 2005
Taro Reports Third Quarter and Nine Month 2005 Results
More